Good day,
Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Before we send you your first edition, please take a moment to confirm your subscription below. We will not be able to send your newsletter until you confirm your subscription.
Confirm Your Subscription Here
The Earnings360 Team
Further Reading from MarketBeat Media Growth Picks: 3 Low-Cost Stocks That Could Double in ValueWritten by Chris Markoch. Published 10/27/2025. 
Key Points - Three undervalued growth stocks trading under $50 could deliver major upside if market conditions strengthen in 2026.
- Equinox Gold, Birkenstock, and Immunocore each carry analyst price targets suggesting 50% to 100% potential gains.
- Rising institutional interest, improving earnings, and biotech innovation make these stocks compelling buy-and-hold opportunities.
Many stocks are objectively overvalued, making it hard for investors to find opportunities that could double in price. Penny stocks (those trading below $5) are a common place to look, but they typically suit only risk-tolerant, nimble investors. There are still opportunities. One way to find them is to look at analyst sentiment. Analysts don't always get it right, but they often have access to data and company resources that retail investors do not. Their views are worth considering as part of due diligence on any stock. With that in mind, here are three stocks trading under $50 per share that analysts see as having notable upside. While analysts aren't necessarily predicting a double for each, their consensus price targets suggest meaningful potential if the economy and company fundamentals cooperate. Equinox Gold: Gold's Momentum Could Keep Running Equinox Gold Corp. (NYSEAMERICAN: EQX) is a Canadian gold mining company. As of Oct. 27, 2025, EQX stock is already up about 100% for the year. Still, analysts give the stock a consensus price target of $26, implying upside of more than 149% from its levels on that date. Equinox is effectively a play on rising gold prices. Many analysts view mining stocks like EQX as an efficient way for equity investors to gain exposure to the gold rally; some of the most bullish forecasts even envision spot gold reaching $5,000 before the end of 2025, with further gains possible in 2026. Higher spot prices improve Equinox's mine economics, but the primary risk is a reversal in the gold trade. Institutional ownership of EQX is relatively low at 38%, yet it has climbed sharply over the past 12 months and has been trending upward for more than two years, which may support further upside. Birkenstock: A Consumer Stock Ready to Rebound It's been a difficult year for consumer discretionary stocks such as Birkenstock Group AG (NYSE: BIRK). BIRK is down about 25% in 2025, but the company may be getting grouped in with a struggling retail sector despite what appear to be solid fundamentals. Year-over-year revenue and earnings are both higher, with revenue posting double-digit growth across segments and channels. Analysts project earnings growth of over 26% for the next 12 months, which lines up with the company's forward price-to-earnings (P/E) ratio of roughly 23x. Short interest in BIRK is around 17% — down over the last month — which could be positive for two reasons: it may indicate short sellers are loosening their positions, and it leaves the potential for a short squeeze if the stock rallies sharply. Analysts give BIRK a consensus price target of $68.38, implying potential upside of about 58%. The company reports third-quarter earnings on Dec. 17, 2025, and stronger-than-expected holiday sales could provide additional momentum heading into 2026. Immunocore: Biotech With Breakthrough Potential Immunocore plc (NASDAQ: IMCR) is a biotechnology company developing cancer treatments using T‑cell technology. As of August 2025, the company has one drug that has successfully completed clinical trials and three candidates in or entering Phase 3 trials. Biotech names are often targeted for their potential to double because a single successful drug approval can dramatically change a company's revenue trajectory. For firms still in the clinical stages, it can be a numbers game: a few wins among many candidates can translate into outsized returns. Immunocore is now generating measurable revenue and may be on a path toward profitability. Analysts give IMCR a consensus price target of $61. More bullishly, HC Wainwright reiterated its Buy rating on Oct. 22, 2025 and assigned a $100 price target. Not all analysts share that optimism: Weiss Research has a Sell rating on the stock, reflecting a view that much of the company's near-term growth may already be priced in. Each of these names carries company- and sector-specific risks. Investors should weigh analysts' opinions alongside their own research, risk tolerance, and investment horizon before making decisions.
| 
